Welcome to our dedicated page for Septerna news (Ticker: SEPN), a resource for investors and traders seeking the latest updates and insights on Septerna stock.
Septerna, Inc. (Nasdaq: SEPN) is a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery and development. News about Septerna often centers on progress across its pipeline of oral small molecule GPCR-targeted therapies, updates on clinical and preclinical programs, and developments related to its proprietary Native Complex Platform™.
Investors following SEPN news can expect regular updates on key programs such as SEP-631, a selective oral small molecule MRGPRX2 negative allosteric modulator (NAM) in a Phase 1 clinical trial for chronic spontaneous urticaria and other mast cell-driven diseases, and SEP-479, a next-generation oral PTH1R agonist development candidate for hypoparathyroidism. Septerna’s news flow also includes information on its TSHR NAM program for Graves’ disease and thyroid eye disease and discovery-stage programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas.
Company announcements frequently highlight financial results, cash position and collaboration-related revenue, particularly from its global collaboration and license agreement with Novo Nordisk A/S to discover and develop oral small molecule therapies for obesity, type 2 diabetes and other cardiometabolic diseases. Septerna also issues news on corporate governance and leadership, such as board appointments, executive role changes and the formation of board committees.
In addition, Septerna regularly announces participation in major healthcare and investor conferences, where management presents business updates and pipeline overviews. For those tracking SEPN, this news page aggregates press releases and related coverage so readers can monitor clinical milestones, collaboration developments, financial disclosures and leadership changes over time.
Septerna (Nasdaq: SEPN) announced management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 2, 2025 at 10:25 a.m. ET in Coral Gables, Florida.
A live webcast will be available in the company's investor relations website and the webcast will be archived for at least 30 days after the presentation.
Septerna (Nasdaq: SEPN) reported third-quarter 2025 results and program milestones on Nov 10, 2025. Key program news: SEP-479 was selected as the next-generation oral PTH1R agonist for hypoparathyroidism after a 7‑day cynomolgus study showing dose‑dependent serum calcium increases and reduced endogenous PTH; a Phase 1 trial is planned in H1 2026. SEP-631 Phase 1 in healthy volunteers is ongoing with initial SAD/MAD and PD readouts expected in H1 2026. Financials: cash, equivalents, and marketable securities of $561.6M (includes $195M Novo Nordisk upfront and $12.5M Vertex milestone); Septerna expects runway into at least 2029. Q3 revenue was $21.5M, R&D expense $24.3M, G&A $7.1M, and net income $8.2M.
Septerna (Nasdaq: SEPN) announced management will participate in two investor conferences in November 2025: a Guggenheim fireside chat on November 10, 2025 at 4:00 p.m. ET and a TD Cowen Immunology & Inflammation Summit fireside chat on November 12, 2025 at 4:00 p.m. ET.
Both presentations will be live webcast and available in the investors section at www.septerna.com. Replays will be archived for at least 30 days after each event.
Septerna (NASDAQ: SEPN), a clinical-stage biotech company focused on G protein-coupled receptor (GPCR) drug discovery, has appointed Dr. Keith Gottesdiener to its Board of Directors. Dr. Gottesdiener, who brings over 30 years of experience in advancing medicines, will chair the newly formed R&D Committee.
Dr. Gottesdiener's extensive background includes serving as CEO of Prime Medicine and Rhythm Pharmaceuticals, where he led the development and approval of setmelanotide. At Merck Research Laboratories, he oversaw the approval of more than 20 novel therapeutics and over 200 successful IND submissions as Worldwide Head of Late-Stage Development.
Septerna (Nasdaq: SEPN), a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery, has announced its participation in two upcoming investor conferences in September 2025.
The company will present at the Cantor Global Healthcare Conference on September 3 at 11:30 a.m. ET and participate in a fireside chat at the Wells Fargo Healthcare Conference on September 5 at 8:45 a.m. ET. Both presentations will be available via webcast on Septerna's website, with replays accessible for 30 days after the events.
Septerna (NASDAQ:SEPN) has initiated its Phase 1 clinical trial for SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM), marking a significant milestone in their drug development program. The trial will evaluate the drug's safety, tolerability, and pharmacological properties in up to 150 healthy adult volunteers.
The study focuses on treating chronic spontaneous urticaria (CSU) and other mast cell-driven diseases. SEP-631 works by selectively blocking MRGPRX2, a GPCR crucial in mast cell activation and degranulation. The trial consists of both single-ascending dose (SAD) and multiple-ascending dose (MAD) components, with SAD dosing already underway.
This development represents a potential breakthrough for patients with CSU, a systemic inflammatory skin disease characterized by persistent itchy hives and angioedema, where current antihistamine treatments often prove inadequate.
Septerna (NASDAQ:SEPN) reported Q2 2025 financial results and business updates, highlighting significant progress across its GPCR drug discovery portfolio. The company's cash position stands at $379.2 million, with runway extended into 2029 following a $195 million upfront payment from Novo Nordisk collaboration.
Key developments include advancing their PTH1R agonist program for hypoparathyroidism with planned Phase 1 trials in H1 2026, initiating Phase 1 trials for SEP-631 in mast cell diseases in Q3 2025, and progressing their TSHR NAM program for Graves' disease. The company also announced the promotion of Liz Bhatt to President, effective August 1, 2025.
Q2 2025 financials showed R&D expenses of $22.2 million and a net loss of $24.8 million, compared to $15.0 million and $16.4 million respectively in Q2 2024.
Septerna (NASDAQ: SEPN), a biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's CEO and Co-founder, Jeffrey Finer, M.D., Ph.D., will deliver a presentation on Thursday, June 5, 2025, at 3:45 p.m. ET in New York. Interested parties can access a live webcast of the presentation through the company's website or the provided link, with the recording remaining available for at least 30 days afterward.
Septerna (NASDAQ: SEPN) reported its Q4 and full year 2024 financial results, highlighting a strong cash position of $420.8 million expected to fund operations into early 2028. The company discontinued its Phase 1 trial of SEP-786 for hypoparathyroidism in February 2025 due to safety concerns, but plans to select a next-generation PTH1R agonist candidate by end of 2025.
Key financial metrics include R&D expenses of $19.3M for Q4 2024 and $65.3M for full year 2024, while G&A expenses were $5.6M for Q4 and $16.6M for full year 2024. Net loss reached $20.7M in Q4 and $71.8M for full year 2024.
The company is advancing multiple programs, including SEP-631, a MRGPRX2 NAM for mast cell diseases, with Phase 1 trial expected in 2025. Additionally, development continues on TSHR NAM compounds for Graves' disease and incretin receptor agonists for metabolic diseases.